Format

Send to

Choose Destination
Semergen. 2015 Oct;41(7):382-6. doi: 10.1016/j.semerg.2015.04.016. Epub 2015 Jul 3.

[Therapeutic equivalence of the new oral anticoagulants].

[Article in Spanish]

Author information

1
Hospital de Úbeda, Úbeda, Jaén, España.
2
Hospital Universitario de Jaén, Jaén, España.
3
Outcomes'10, Universitat Jaume I, Castellón de la Plana, España. Electronic address: lizan@outcomes10.com.

Abstract

In an attempt to minimize the economic impact due to the incorporation of innovative drugs, health authorities have promoted and supported the evaluation and market positioning of drugs, as equivalent therapeutic alternatives. This issue has recently gained importance, possibly due to the current economic crisis. The equivalent therapeutic alternatives are justified by the need to compete on price, and by the authorities recommendation to establish therapeutic equivalence, price and financing of medicinal products at the same time. The establishment of the new oral anticoagulants and the equivalent therapeutic alternatives is a problematic issue if it is based on the absence of direct comparisons between different drugs and the questionable methodology used in the current indirect comparisons. Currently, it is difficult to determine when a new oral anticoagulant is more recommendable than others, but efforts are being made in order to propose alternatives for the decision based on patient characteristics.

KEYWORDS:

Anticoagulantes orales; Economic impact; Equivalencia terapéutica; Impacto económico; Oral anticoagulants; Therapeutic equivalence

PMID:
26146035
DOI:
10.1016/j.semerg.2015.04.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center